Australia Cancer Immunotherapy Market Size & Outlook

Monoclonal antibodies was the largest segment with a revenue share of 68.29% in 2023. Horizon Databook has segmented the Australia cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.

Checkpoint inhibitors have heralded a new era for cancer treatment in Australia, with Opdivo and Keytruda at the forefront. Among all cancers, cancer immunotherapy was deemed most successful in the treatment of melanoma, which records the highest prevalence in Australia.

Monotherapy or combinatorial immunotherapy has been successfully applied in over 50% of melanoma patients and is likely to demonstrate similar results in lung & kidney cancer over the forecast period. Checkpoint inhibitors have also proved effective in the treatment of HNSCC, bladder cancer, and Hodgkin lymphoma.

Favorable reimbursement schemes in the country is an additional driving factor of the cancer immunotherapy market. A possible alternate strategy being discussed across medical reimbursement forums in Australia is the pay-for-performance scheme, wherein manufacturers are reimbursed only if the drug is successful in patients.